Phase 3, Double-Blind, Placebo-Controlled Study of MEDI4736 After Chemoradiation in Stage III, Locally Advanced, Unresectable NSCLC (PACIFIC)

被引：0
|
作者：
Cho, Byoung Chul [1 ]
Kim, Joo-Hang [1 ]
Villegas, Augusto [2 ]
Frusch, Nicolas [3 ]
Murakami, Shuji [4 ]
Shi, Kelvin [5 ]
Ibrahim, Ramy [5 ]
Ballas, Marc [5 ]
Antonia, Scott J. [6 ]
机构：
[1] Yonsei Univ Hlth Syst, Severance Hosp, Yonsei Canc Ctr, Seoul, South Korea
[2] Canc Specialists North Florida, Jacksonville, FL USA
[3] Ctr Hosp Ardenne, Libramont, Belgium
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa 2410815, Japan
[5] Astrazeneca, Gaithersburg, MD USA
[6] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; MEDI4736; PD-L1; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-090
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [41] A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non-small cell lung cancer: TORG1937 (DATE study).
    Nakamichi, Shinji
    Kubota, Kaoru
    Misumi, Toshihiro
    Murakami, Shuji
    Kondo, Tetsuro
    Okamoto, Isamu
    Minato, Koichi
    Harada, Daijiro
    Isobe, Kazutoshi
    Itani, Hidetoshi
    Takata, Saori
    Wakui, Hiroshi
    Misumi, Yuki
    Ikeda, Satoshi
    Asao, Tetsuhiko
    Inoue, Takeo
    Hosokawa, Shinobu
    Kobayashi, Yumiko
    Takiguchi, Yuichi
    Okamoto, Hiroaki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
    Chesney, Jason A.
    Ribas, Antoni
    Long, Georgina, V
    Kirkwood, John M.
    Dummer, Reinhard
    Puzanov, Igor
    Hoeller, Christoph
    Gajewski, Thomas F.
    Gutzmer, Ralf
    Rutkowski, Piotr
    Demidov, Lev
    Arenberger, Petr
    Shin, Sang Joon
    Ferrucci, Pier Francesco
    Haydon, Andrew
    Hyngstrom, John
    van Thienen, Johannes, V
    Haferkamp, Sebastian
    Guilera, Josep Malvehy
    Rapoport, Bernardo Leon
    VanderWalde, Ari
    Diede, Scott J.
    Anderson, James R.
    Treichel, Sheryl
    Chan, Edward L.
    Bhatta, Sumita
    Gansert, Jennifer
    Hodi, Frank Stephen
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 528 - +
  • [43] A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke
    Sonde, L
    Nordström, M
    Nilsson, CG
    Lökk, J
    Viitanen, M
    CEREBROVASCULAR DISEASES, 2001, 12 (03) : 253 - 257
  • [44] Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
    Evans, T. R. J.
    Van Cutsem, E.
    Moore, M. J.
    Bazin, I. S.
    Rosemurgy, A.
    Bodoky, G.
    Deplanque, G.
    Harrison, M.
    Melichar, B.
    Pezet, D.
    Elekes, A.
    Rock, E.
    Lin, C.
    Strauss, L.
    O'Dwyer, P. J.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 354 - 361
  • [45] Pharmacokinetics and pharmacodynamics of ISA247 in a Phase III, randomized, multicenter, double-blind, placebo-controlled study
    Wasel, N
    Gupta, A
    Tomi, Z
    Papp, K
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB9 - AB9
  • [46] Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
    Xu, Jianming
    Shen, Lin
    Zhou, Zhiwei
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Ying, Jieer
    Yu, Xianjun
    Qin, Shukui
    Yuan, Xianglin
    Zhang, Tao
    Deng, Yanhong
    Xiu, Dianrong
    Cheng, Ying
    Tao, Min
    Jia, Ru
    Wang, Wei
    Li, Jing
    Fan, Songhua
    Peng, Mengye
    Su, Weiguo
    LANCET ONCOLOGY, 2020, 21 (11): : 1500 - 1512
  • [47] Tadalafil therapy in pulmonary arterial hypertension: results of a randomized, double-blind, placebo-controlled, phase III study
    Galie, N.
    Brundage, B. H.
    Ghofrani, A.
    Oudiz, R. J.
    Simonneau, G.
    Beardsworth, A.
    Chan, M.
    Barst, R. J.
    EUROPEAN HEART JOURNAL, 2008, 29 : 519 - 519
  • [48] Prevention of irinotecan-induced diarrhea by probiotics: Randomized double-blind, placebo-controlled phase III study
    Mego, Michal
    Chovanec, Jozef
    Andrezalova, Iveta
    Konkolovsky, Peter
    Mikulova, Milada
    Reckova, Maria
    Miskovska, Vera
    Bystricky, Branislav
    Medvecova, Lenka
    Mikusova, Dagmar
    Lagin, Adela
    Svetlovska, Daniela
    Spanik, Stanislav
    Mardiak, Jozef
    Zajac, Vladimir
    Drgona, Lubos
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients
    Masato Murakami
    Kenichi Osada
    Hiromichi Mizuno
    Toshimitsu Ochiai
    Levent Alev
    Kusuki Nishioka
    Arthritis Research & Therapy, 17
  • [50] A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with Fibromyalgia
    Mease, Philip J.
    Russell, I. Jon
    Arnold, Lesley M.
    Florian, Hana
    Young, James P.
    Martin, Susan A.
    Sharma, Uma
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (03) : 502 - 514
12345